newsfilter
← Latest News
GlobeNewswire·

Kineta to Present Preclinical Data on VISTA Blocking KVA12123 at Immuno US 2023

KA

SEATTLE, Oct. 09, 2023 (GLOBE NEWSWIRE) -- Kineta, Inc. (NASDAQ:KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance,